index
Ace Inhibitors, 268, 280
Advertising, 75–76, 112, 118–19, 180, 371,
387
Affinity–ties, 175
African-American Heart Failure Trial
(v-heFT), 264, 270, 272–73, 275, 277,
284
Agency, 9, 177, 188
Aging, 16, 18, 25, 79, 290–92, 299
Alternative medicine, 15, 75–76, 110, 139,
141, 383; acupuncture and, 139–40;
chiropractic and, 129, 139; homeopa-
thy and, 118–120; National Center
for Complementary and Alternative
Medicine, 15
American Cancer Society, 335–37
American Medical Association, 110, 113,
116, 122, 125
Andrology, 159
Antibiotics: penicillin, 122, 125–26
Assemblage, 392, 402–3
Assisted reproduction, 178, 180
Association of Black Cardiologists, 275
Bayh-Dole Act, 264–65, 267
Behavior modification, 80
BiDil: approval of, 263; as model for
drug development, 276, 278–81; bio-
medicalization and, 263, 265, 274;
clinical trials for, 264–65; health dis-
parities and, 281–84; heart failure
statistics and, 272–74; legal construc-
tion of, 267–72; marketing of, 275–77;
media coverage of, 279–80; origins of,
266–67; racialization of, 265, 269–70,
283–84
Big Pharma, 21
Biocapital, 8–10, 13, 22, 29, 38, 386, 397–
98; biopiracy and, 10, 381; biovalue
and, 9; through reproduction, 9–10
Bioeconomy (biopolitical economy), 1,
7–8, 22–23, 39, 182, 210, 382, 397; bio-
available zones and, 9; bioeconomic
potential and, 23; biosecurity and, 41;
governance and, 42, 182; health and
illness in, 31; risk management and,
182
Bioinformatics, 69
Biology: biologization, 29; molecular,
68–69; relatedness and, 178, 186
Biomedical TechnoService Complex
Inc., 22, 49, 57, 198, 202, 207–9, 215
Biopolitics, 4, 29, 155, 161, 242, 401; bio-
political citizenship and, 13–14, 23,
36, 39
Biopower, 4–5, 39, 239–41, 244, 259, 260
Biopsychiatry, 38, 354–55, 364, 376
Previous Page Next Page